PomDoctor Ltd. Unsponsored ADR ( (POM) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PomDoctor Limited, which trades in the U.S. via an unsponsored ADR, has filed a Form 12b-25 notifying investors of a delay in its annual Form 20-F (Yearly Report) for the year ended December 31, 2025. The company says it cannot meet the deadline because it needs more time to review and finalize its consolidated financial statements for inclusion in the report.
Management states that the delay stems from the extra time required to complete this financial review, rather than from any disclosed issue with auditors, internal controls, or governance committees. The filing indicates that all other required periodic reports over the past 12 months have been submitted on time, suggesting this is an isolated timing issue rather than part of a broader compliance problem.
Under the relief sought, PomDoctor expects to file the delayed Form 20-F (Yearly Report) within 15 calendar days after the original SEC due date. The company further notes that it plans to submit the annual report as soon as the audited consolidated financial statements become available from its independent registered public accounting firm.
PomDoctor does not anticipate any significant change in its results of operations compared with the prior fiscal year, based on current information. However, it cautions that the final numbers could still change once the external audit is complete, and it highlights that these expectations are forward-looking statements subject to risks and uncertainties.
The company emphasizes that its ability to file future SEC reports on time will depend on the completion of audit work and verification of financial data. The notification is signed on behalf of PomDoctor Limited by Chairman and Chief Executive Officer Zhenyang Shi, dated April 30, 2026, underscoring executive-level responsibility for ongoing reporting compliance.
Spark’s Take on POM Stock
According to Spark, TipRanks’ AI Analyst, POM is a Neutral.
The score is driven primarily by weak financial fundamentals (persistent losses and negative equity) and bearish technical momentum (negative MACD, price below key moving averages). Valuation impact is limited because P/E and dividend data were not provided.
To see Spark’s full report on POM stock, click here.
More about PomDoctor Ltd. Unsponsored ADR
Average Trading Volume: 1,101,696
Technical Sentiment Signal: Strong Sell
Current Market Cap: $44.32M
For detailed information about POM stock, go to TipRanks’ Stock Analysis page.